Back to top
more

Insmed (INSM)

(Delayed Data from NSDQ)

$24.80 USD

24.80
1,294,138

-0.12 (-0.48%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $24.50 -0.30 (-1.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -13.27% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -3.77% and 0.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

by Zacks Equity Research

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -61.82% and 9.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 182.35% and 49.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -8.33% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -22.47% and 0.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Insmed (INSM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.